SCHEMBL317787

SCHEMBL317787

FC(F)(F)c1cccc2c(Cl)ccnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.51
KDM4E B2RXH2 5/20 0.49
TDP1 Q9NUW8 4/20 0.49
MEN1 O00255 3/20 0.49
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 3/20 0.49
PARP1 P09874 1/20 0.49
NR1H2 P55055 7/20 0.46
NR1H3 Q13133 7/20 0.46
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
DYRK3 O43781 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
CDK1 P06493 1/20 0.44
CDK2 P24941 1/20 0.44
FLT4 P35916 1/20 0.44
CSNK1D P48730 1/20 0.44
CLK2 P49760 1/20 0.44
LIMK1 P53667 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30880479 1.00 NCF1 (0.51) NCF1KDM4ETDP1MEN1ALDH1A1
SCHEMBL4148183 0.86 KDM4E (0.56) KDM4ETDP1MEN1ALDH1A1KMT2A
SCHEMBL27991176 0.84 KDM4E (0.50) NCF1KDM4ETDP1MEN1ALDH1A1
SCHEMBL16248304 0.80 NCF1 (0.52) NCF1KDM4EMEN1KMT2APARP1
SCHEMBL9033424 0.80 PSMD14 (0.62) NCF1ALDH1A1PARP1NR1H2NR1H3
SCHEMBL6230425 0.79 CCR1 (0.37) NCF1KDM4ETDP1MEN1ALDH1A1
SCHEMBL29862680 0.79 NCF1 (0.51) NCF1KDM4ETDP1MEN1ALDH1A1
SCHEMBL2876594 0.79 NR4A2 (0.56) NCF1MEN1KMT2APARP1NR1H2
SCHEMBL7757756 0.79 NCF1 (0.55) NCF1MEN1KMT2APARP1NR1H2
SCHEMBL2876591 0.79 NCF1 (0.51) NCF1TDP1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
US-5897940-A Ink jet transparencies XEROX CORPORATION (US) 1999-04-27 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
US-20250034139-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY PHARMA CINQ, LLC 2025-01-30 US disclosed
US-12139483-B2 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity PHARMA CINQ, LLC (US) 2024-11-12 US disclosed
US-20240360131-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 US disclosed
US-12065437-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-20 US disclosed
US-20230086683-A1 PLATELET STORAGE METHODS AND COMPOSITIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-03-23 US disclosed
EP-4090657-A1 PLATELET STORAGE METHODS AND COMPOSITIONS Platefuse, Inc. (US) 2022-11-23 EP disclosed
US-11351164-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use BRISTOL-MYERS SQUIBB COMPANY (US) 2022-06-07 US disclosed
US-20210283123-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE BRISTOL-MYERS SQUIBB COMPANY 2021-09-16 US disclosed
US-4277607-A Process for the preparation of 4-chloroquinolines ROUSSEL UCLAF (FR) 1981-07-07 US disclosed
EP-0001175-B1 4-AMINOQUINOLINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JOHN WYETH & BROTHER LIMITED (GB) 1981-04-15 EP disclosed
US-4259335-A 1-Methyl-4-piperidinol esters of 4-quinolinylamino benzoates and antiinflammatory and analgesic compositions and methods employing them SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) 1981-03-31 US disclosed
US-4233305-A ANALGESICS ROUSSEL UCLAF (FR) 1980-11-11 US disclosed
US-4160828-A ANTIINFLAMMATORY AND ANTIRHEUMATIC HOECHST AKTIENGESELLSCHAFT (DE) 1979-07-10 US disclosed
EP-0001175-A1 4-Aminoquinoline derivatives, a process for their preparation and pharmaceutical compositions containing them JOHN WYETH & BROTHER LIMITED (GB) 1979-03-21 EP disclosed
US-4091095-A DIALKYLPHOSPHINYL-ALKYL ESTER OF A 2-(ARYL-AMINO) BENZOIC ACID, ANALGESICS HOECHST AKTIENGESELLSCHAFT (DT) 1978-05-23 US disclosed
US-4025629-A HYPOTENSIVES, ANTIANXIETY THE UPJOHN COMPANY (US) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11351164-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use IDO1, IDO2, INMT NCF1 2041/4885KDM4E 362/4885TDP1 1200/4885
US-20210283123-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE IDO1, IDO2, INMT NCF1 2041/4885KDM4E 362/4885TDP1 1200/4885
US-20230086683-A1 PLATELET STORAGE METHODS AND COMPOSITIONS PLTP, PFKP, MPL NCF1 1123/4885KDM4E 4505/4885TDP1 357/4885
US-20250034139-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY AADAC, CASP1, AAAS NCF1 384/4885KDM4E 1059/4885TDP1 2102/4885
US-12065437-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS NCF1 1464/4885KDM4E 1500/4885TDP1 1573/4885
US-12139483-B2 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity NOD1, NLRP3, AADAC NCF1 448/4885KDM4E 1620/4885TDP1 3015/4885
US-20240360131-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS NCF1 1464/4885KDM4E 1500/4885TDP1 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.